Seeking Clues to Johnson & Johnson (JNJ) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics

Core Insights - Analysts expect Johnson & Johnson (JNJ) to report quarterly earnings of $2.57 per share, reflecting a year-over-year decline of 5.2% [1] - Revenue projections stand at $21.66 billion, indicating a 1.3% increase from the previous year [1] - The consensus EPS estimate has been adjusted downward by 0.3% over the past 30 days, showing a reassessment by analysts [1] Revenue and Sales Estimates - The consensus estimate for 'Sales- MedTech- Total' is $8.16 billion, suggesting a year-over-year increase of 4.3% [3] - 'Sales- Innovative Medicine- WW' is projected to reach $13.49 billion, indicating a decline of 0.5% year over year [4] - 'Sales- MedTech- Surgery- WW' is expected to be $2.41 billion, also reflecting a decrease of 0.5% year over year [4] - 'Sales- Innovative Medicine- Oncology- WW' is forecasted to reach $5.58 billion, showing a significant increase of 15.9% from the previous year [4] Specific Product Sales Projections - 'Sales- Innovative Medicine- Oncology- CARVYKTI- WW' is estimated at $341.85 million, representing a substantial increase of 117.7% year over year [5] - 'Sales- Innovative Medicine- Neuroscience- SPRAVATO- WW' is projected to be $319.68 million, indicating a year-over-year increase of 42.1% [5] - 'Sales- MedTech- Cardiovascular- ABIOMED- WW' is expected to reach $408.39 million, reflecting a 10.1% increase year over year [6] - 'Sales- MedTech- Cardiovascular- Other Cardiovascular- WW' is estimated at $94.89 million, suggesting a 3.1% increase from the previous year [6] Orthopaedics Sales Estimates - 'Sales- MedTech- Orthopaedics- Hips- US' is projected at $268.43 million, indicating a decline of 0.6% year over year [7] - 'Sales- MedTech- Orthopaedics- Hips- International' is expected to be $154.50 million, reflecting a 1.6% increase year over year [7] - 'Sales- MedTech- Orthopaedics- Knees- US' is estimated at $240.27 million, suggesting a decrease of 0.7% year over year [8] Overall Performance and Market Position - Organic Sales Growth (Operational growth) is anticipated to reach 3.7%, slightly down from 3.9% reported in the same quarter last year [8] - JNJ shares have returned -7.3% over the past month, compared to a -5.3% change in the Zacks S&P 500 composite [8] - With a Zacks Rank 3 (Hold), JNJ is expected to perform in line with the overall market in the near future [8]